Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients

Journal of Thoracic Oncology

Volumn 1, Issue 6, 2006, Pages 520-525

  Chang, Gee Chen ^a,b,g   Tsai, Chun Ming ^c,d   Chen, Kun Chieh ^a   Yu, Chong Jen ^e   Shih, Jin Yuan ^e   Yang, Tsung Ying ^a   Lin, Ching Pei ^a   Hsu, Jeng Yuan ^a,f   Chiu, Chao Hua ^c   Perng, Reury Perng ^c,d   Yang, Pan Chyr ^e   Yang, Chih Hsin ^e  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Chemonaive; Gefitinib; Non small cell lung cancer; Performance status; Predictive factor

Indexed keywords

GEFITINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG RESPONSE; DYSPNEA; FEMALE; FOLLOW UP; GENDER; HISTOPATHOLOGY; HUMAN; INTERSTITIAL PNEUMONIA; LIVER DYSFUNCTION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; PARONYCHIA; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN TOXICITY; SMOKING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TAIWAN; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; ANALYSIS OF VARIANCE; CANCER STAGING; COHORT ANALYSIS; DOSE RESPONSE; DRUG ADMINISTRATION; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROBABILITY; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME;

EID: 33750051006     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200607000-00004     Document Type: Article

References (47)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Fossella FV, Lee JS, Hong WK. Management strategies for recurrent non-small cell lung cancer. Semin Oncol 1997;24:455-462.
3. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.
4. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
5. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2006;366:1527-1537.
6. Goto K, Kim E, Kubota K, et al. Association of multiple pulmonary metastases with response to gefitinib in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 2004;23:637..
7. Han S, Hwang PG, Chung DH, et al. Gefitinib monotherapy in previously treated advanced non-small cell lung cancer (NSCLC): an immunohistochemical (IHC) analysis of EGFR and its downstream molecules. Proc Am Soc Clin Oncol 2004;23:637.
8. Hotta K, Harita S, Bessho A, et al. Interstitial lung disease (ILD) during gefitinib treatment in Japanese patients with non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group. Proc Am Soc Clin Oncol 2004;23:629.
9. Park J, Park BB, Kim JY, et al. Gefitinib (ZD1839) Monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 2004;10:4383-4388.
10. Seto T, Yamamoto N. Interstitial lung disease (ILD) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC): results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey. Proc Am Soc Clin Oncol 2004;23:629.
11. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104.
12. Zhang X, Li L. Evaluation of safety and efficacy of ZD1839 as monotherapy for Chinese patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2004;23:636.-
13. Chiu CH, Tsai CM, Chen YM, et al. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2006;47:129-138.
14. Lim ST, Wong EH, Chuah KL, et al. Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients. Br J Cancer 2006;93:23-28.
15. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
16. Chang GC, Yang TY, Chen KC, et al. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:4646-4648.
17. Su WP, Yang CH, Yu CJ, Shih JY, Hsu C, Yang PC. Gefitinib treatment for nonsmall cell lung cancer - a study including patients with poor performance status. J Formos Med Assoc 2006;104:557-562.
18. Braconi C, Salvagni S, Scartozzi M, et al. ZD1839 for compassionate use in pretreated patients (pts) with advanced non-small cell lung cancer (ANSCLC). Proc Am Soc Clin Oncol 2003;22.
19. Cavina R, Soto Parra HJ, Zucali PA, et al. ZD 1839 (Iressa) in elderly patients with progressive pretreated non small cell lung cancer (NSCLC): results at the Istituto Clinico Humanitas, Rozzano, Milano. Lung Cancer 2003;41:S248.
20. Copin M, Kommareddy A, Behnken D, et al. Gefitinib in elderly patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003;22.
21. Dickson N, Hainsworth JD, Spigel DR, et al. Single agent gefitinib in poor performance status patients with previously untreated advanced non-small cell lung cancer: a Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 2004;23:634.
22. Haringhuizen A, Vaessen HFR, Baas P, et al. Gefitinib (ZD 1839, Iressa) as a last option for patients with recurrent non-small cell lung cancer (NSCLC). Lung Cancer 2003;41:S248.
23. Janne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 2004;44:221-230.
24. Kommareddy A, Coplin M, Gao F, et al. Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University Experience. Lung Cancer 2004;45:221-225.
25. Lopez-Martin A, Constela M, Martin Algarra S, et al. ZD1839 in advanced non-small cell lung cancer (NSCLC) patients progressed to chemotherapy (CT). Proc Am Soc Clin Oncol 2003;22:670..
26. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-1109.
27. Mohamed M, Ramalingam S, Lin Y, et al. Skin rash and good performance status (PS) predict improved survival with gefitinib for patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23:637..
28. Pallis AG, Mavroudis D, Androulakis N, et al. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. Lung Cancer 2003;40:301-307.
29. Parton M, Maisey N, Banerjee S, et al. Gefitinib in patients with non-small cell lung cancer (NSCLC): the Royal Marsden experience. Proc Am Soc Clin Oncol 2004;23:638.
30. Polowy C, Coon J, Villaflor V, et al. Potential molecular prognostic factors in non-small cell lung cancer (NSCLC) patients treated with gefitinib. Proc Am Soc Clin Oncol 2004;23.
31. Reiling R, Wade JL, Govindan R, et al. Clinical benefit with compassionate use gefitinib in a subset of non-small-cell lung cancer (NSCLC) patients with the bronchoalveolar (BAC) subtype treated during an expanded access program (EAP). Proc Am Soc Clin Oncol 2004;23:635.
32. West H, Franklin WA, Gumerlock PH, et al. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Proc Am Soc Clin Oncol 2004;23:618.
33. Zinner R, Govindan R, Wozniak AJ, et al. Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP). Proc Am Soc Clin Oncol 2004;23:633.
34. Argiris A, Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 2004;43:317-322.
35. Lee DH, Han JY, Lee HG, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2006;11:3032-3037.
36. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
37. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
38. Pao W, Miller VA, Venkatraman E, et al. Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt? J Natl Cancer Inst 2004;96:1117-1119.
39. Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2006;11:3750-3757.
40. Kosaka T, Endoh H, Yatabe Y, et al. Translational research on lung cancer-EGFR gene mutation. Gan To Kagaku Ryoho 2006;32:750-758.
41. Shih JY, Gow CH, Yu CJ, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006;118:963-969.
42. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2006;11:1167-1173.
43. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2006;97:643-655.
44. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2006;97:339-346.
45. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2006;23:857-865.
46. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2006;23:6829-6837.
47. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-139.